BRC Therapeutics

The supplied evidence does not contain any information about BRC Therapeutics. The two snippets are Chinese-language securities research pages from Sina Finance: one is an equity-strategy report on Beijing Stock Exchange merger-and-acquisition activity (centered on the software firm Airong Software's acquisition of Beijing Renhe Chuangjian), and the other is a generic list of company research reports covering unrelated listed companies such as Bank of Ningbo, Sanhua Intelligent Controls and Luzhou Laojiao. Neither mentions BRC Therapeutics, a biopharmaceutical company, a therapeutic product, a founder, a headquarters, or any ownership structure. Because no brand-sense evidence was provided, this entry is intentionally kept short and flagged for review. Any substantive dossier — therapeutic pipeline, platform technology, financing history, leadership, or market positioning — would require verifiable sources that were not supplied here, and inventing such details would be inappropriate. If BRC Therapeutics is indeed a clinical-stage biotech or a therapeutics brand, the correct next step is to supply its official website, press releases, or regulatory filings so that a full bilingual dossier can be written from primary evidence.

• 2026.08.24

  Reported2026.08.24

  BRC Therapeutics appoints Chandra Ramanathan as Executive Vice President of Commercialization and Strategy[3]BRC Therapeutics任命Chandra Ramanathan为商业化与战略执行副总裁prnewswire.com

  BRC Therapeutics, a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics, announced the appointment of Chandra Ramanathan, Ph.D., M.B.A., as Executive Vice President of Commercialization and Strategy. Ramanathan previously served at Danaher Corporation and spent more than 12 years at Bayer.

Read more

1. 1北交所策略专题报告：艾融软件1.4亿收购北京人和切入电力AI及金融科技 北交所并购六条已62起重要案例__新浪财经_新浪网stock.finance.sina.com.cn
2. 2公司研究研究报告|研究评级|机构研报_新浪财经_新浪网stock.finance.sina.com.cn
3. 3BRC Therapeutics任命Chandra Ramanathan为商业化与战略执行副总裁prnewswire.com